Trial Profile
Phase II Trial of Bicalutamide and RAD001 in Patients With Hormone-Independent Prostatic Adenocarcinoma (HIPC) After the First-Line Androgen Deprivation Therapy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Bicalutamide
- Indications Prostate cancer
- Focus Therapeutic Use
- 28 Mar 2016 Results published in the Cancer
- 07 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 May 2015 Planned End Date changed from 1 Jan 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.